Sep 27, 2022 7:30 am EDT Opus Genetics Expands Board of Directors with Appointment of Global Ophthalmology Leader Dr. Adrienne Graves
Sep 15, 2022 7:00 am EDT Ocuphire Announces Upcoming Presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting
Sep 12, 2022 8:34 am EDT Opus Genetics Leadership to Present at 3rd Annual Gene Therapy for Ophthalmic Disorders Conference
Sep 12, 2022 8:00 am EDT Ocuphire Pharma Receives PDFUA Fee Waiver for Nyxol New Drug Application from FDA
Sep 8, 2022 8:00 am EDT Ocuphire Pharma Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy
Sep 6, 2022 9:00 am EDT Ocuphire Pharma to Present at The H.C. Wainwright 24th Annual Global Investment Conference
Sep 1, 2022 8:28 am EDT Opus Genetics Hosts Inaugural Patient Advocacy Outreach Webinar on Inherited Retinal Diseases
Aug 12, 2022 7:00 am EDT Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update
Aug 8, 2022 7:00 am EDT Ocuphire Pharma Announces Upcoming Presentations at Two Conferences in August
Aug 3, 2022 8:00 am EDT Ocuphire Extends U.S. Patent Protection for Late-Stage Drug Candidate Nyxol® for Reversal of Mydriasis by Five More Years into 2039 with New Patent Issuance